Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06941467 · ClinicalTrials.gov registry record · Phase 1

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

A Phase 1 study of Wound Healing and Mohs Micrographic Surgery, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 1
Development phase
102
Enrollment target
1
Study location

NCT06941467: Recruiting Phase 1 study of Wound Healing and Mohs Micrographic Surgery, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06941467 is a Phase 1 study of Wound Healing and Mohs Micrographic Surgery that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 102 participants, above the 48-participant average among 11 other Wound Healing trials with a reported enrollment target (113% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06941467, a Phase 1 study of Wound Healing and Mohs Micrographic Surgery, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 1
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

Topical timolol, a β2-Adrenergic receptor (B2AR) antagonist, has demonstrated promise in wound healing over the past several years. The majority of the literature has evaluated the use of topical timolol to shorten wound healing time in chronic wounds of non-surgical etiologies. To date, there are no prospective randomized clinical trials evaluating the role of topical timolol for shortening wound healing time in acute open surgical wounds. Therefore, the purpose of this study is to determine whether or not topical timolol solution decreases time to wound healing in patients with defects after Mohs Micrographic Surgery (MMS) that cannot be closed with sutures and are left to heal by second intent. The research team also will look to determine if there is a difference in cosmesis of wounds treated with topical timolol compared to those treated with the standard of care. The present study will primarily focus on wounds in the distal lower extremity as these are most commonly left to heal by secondary intent

Primary Outcome

The wound surface area healing (skin reepithelialization) in open post-surgical lower extremity wounds will be measured using a ruler.

Interventions

  • OTHER Standard of Care
  • DRUG Timolol Maleate Solution

Study Locations (1)

New York

  • Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2025-01-03
Est. Completion 2026-04-01
Phase Phase 1

What NCT06941467 shows while recruiting

NCT06941467 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, above the 48-participant average among 11 other Wound Healing trials with a reported enrollment target (113% higher).

The record links to 2 conditions, with Wound Healing appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT06941467 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06941467 about?

NCT06941467 is a clinical study titled "Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds". Topical timolol, a β2-Adrenergic receptor (B2AR) antagonist, has demonstrated promise in wound healing over the past several years. The majority of the literature has evaluated the use of topical timolol to shorten wound healing time in chronic wounds of non-surgical etiologies. To date, there are n...

What is the current status of trial NCT06941467?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2025-01-03. Estimated completion is 2026-04-01.

What conditions does trial NCT06941467 study?

This clinical trial studies the following conditions: Wound Healing, Mohs Micrographic Surgery.

What interventions are being tested in trial NCT06941467?

The interventions under investigation include: Standard of Care (OTHER), Timolol Maleate Solution (DRUG).

Who is sponsoring clinical trial NCT06941467?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06941467 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Healing

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06941467's enrollment target sits among peer trials

102 2nd of 11 the highest of 11 other Wound Healing trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wound Healing trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06941467, the US trial registry maintained by the National Library of Medicine. NCT06941467 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.